Ex-Takeda exec Tadataka Yamada rejoins Frazier Healthcare
This article was originally published in Scrip
Executive Summary
Frazier Healthcare, a provider of growth capital to healthcare companies, has announced Dr Tadataka Yamada will rejoin the firm. He will serve as a venture partner on the life sciences team, focused on creating new companies as well as providing strategic guidance to existing portfolio companies. He will also be a senior advisor to the growth buyout team, where he will provide advice on opportunities in pharmaceutical services and spin-outs from large healthcare companies, and sit on boards of portfolio companies such as PCI, a large pharmaceutical services company in the Frazier portfolio. Before rejoining Frazier, Dr Yamada was chief medical and scientific officer at Takeda Pharmaceuticals in Tokyo, as well as a member of the company's board of directors. Previously he was chair of R&D at GlaxoSmithKline and a member of the company's board.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.